Seer’s Proteograph to Profile Plasma Proteome in 10,000 PRECISE-SG100K Samples
Seer’s Proteograph will deeply profile plasma proteomes in 10,000 PRECISE-SG100K participants, combining data with Thermo Fisher’s Olink Reveal and Orbitrap Astral for enhanced multi-omic insights. The initiative embeds unbiased proteomics into a 100,000-participant, multi-ancestry Singapore cohort to accelerate biomarker discovery and precision health.
1. Collaboration Scope
Seer’s Proteograph Product Suite has been selected to analyze plasma samples from 10,000 participants in the PRECISE-SG100K study, a landmark multi-ancestry cohort of 100,000 Singapore residents. The workflow will be combined with Thermo Fisher’s Olink Reveal assays and Orbitrap Astral mass spectrometers to generate a comprehensive proteomic dataset.
2. Proteomic Workflow Advantages
The Proteograph–Astral combination delivers high-throughput, deep proteome coverage with peptide-level resolution, providing thousands of quantified proteins per sample. This mass spectrometry–based approach complements affinity platforms by validating and extending detected signals, strengthening biomarker validation and target discovery.
3. Strategic Implications
Embedding unbiased plasma proteomics into a population-scale study positions Seer as a leading provider for precision health initiatives. The collaboration is expected to drive adoption of Proteograph in large-scale research, support drug target biology, and inform risk models across diverse populations.